Drug
Opc 167832
Opc 167832: highest development phase Phase 1/2, developed by Otsuka. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| 10 mg OPC-167832 NCT03678688 | Phase 1/2 | Pulmonary TB |
Latest
No recent events.
Follow Opc 167832 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.